M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

BATTLE Program: Umbrella Protocol for Patients With Non-Small Cell Lung Cancer (NSCLC)

Completed

Conditions: Lung Cancer

Interventions: Procedure: Tumor Biopsy

First Posted Date: 2006-12-12

Last Posted Date: 2020-01-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 341

Registration Number: NCT00409968

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Thymoglobulin (ATG) Dose Finding Study

Phase 1

Terminated

Conditions: Graft vs Host Disease

Interventions: Drug: High Dose Thymoglobulin (ATG)
Drug: Low Dose Thymoglobulin (ATG)

First Posted Date: 2006-12-11

Last Posted Date: 2012-01-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT00409695

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

Amifostine With IMRT for Submandibular and Sublingual Salivary Sparing During Head and Neck Cancer Treatment

Phase 2

Terminated

Conditions: Head and Neck Cancer

Interventions: Drug: Amifostine
Procedure: Intensity- Modulated Radiation Therapy

First Posted Date: 2006-12-08

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT00409331

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma

Phase 1

Completed

Conditions: Mesothelioma

Interventions: Drug: Cisplatin
Drug: Imatinib Mesylate
Drug: Pemetrexed
Drug: Dexamethasone

First Posted Date: 2006-11-22

Last Posted Date: 2015-11-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 19

Registration Number: NCT00402766

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Erlotinib Prevention of Oral Cancer (EPOC)

Phase 3

Completed

Conditions: Oral Cancer

Interventions: Drug: Placebo
Drug: Erlotinib

First Posted Date: 2006-11-22

Last Posted Date: 2020-04-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 303

Registration Number: NCT00402779

Locations: 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
The Univeristy of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 1 locations

Malignant Pleural Effusion With ZD6474

Phase 2

Terminated

Conditions: Lung Cancer
Pleural Effusion

Interventions: Drug: ZD6474

First Posted Date: 2006-11-22

Last Posted Date: 2016-03-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 28

Registration Number: NCT00402896

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Phase 1

Completed

Conditions: Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Thymoglobulin
Drug: Busulfan
Drug: Fludarabine
Procedure: Alloreactive NK Infusion
Drug: G-CSF
Drug: Tacrolimus
Drug: Methotrexate
Drug: Interleukin-2

First Posted Date: 2006-11-22

Last Posted Date: 2015-05-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT00402558

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)

Phase 2

Completed

Conditions: Acute Myelogenous Leukemia

Interventions: Drug: Decitabine

First Posted Date: 2006-11-14

Last Posted Date: 2013-03-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT00398983

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Chemoradiation-Induced Nausea and Emesis: Quality of Life

Terminated

Conditions: Gastric Cancer
Anal Cancer
Pancreatic Cancer
Vulvar Cancer
Cervical Cancer
Endometrial Cancer

Interventions: Behavioral: Interview
Other: Questionnaire

First Posted Date: 2006-11-01

Last Posted Date: 2020-01-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 207

Registration Number: NCT00394602

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Targeted Intervention for Melanoma Prevention

Not Applicable

Completed

Conditions: Melanoma

Interventions: Behavioral: Interview

First Posted Date: 2006-10-31

Last Posted Date: 2019-09-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 205

Registration Number: NCT00394134

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy